Mesoporous hydroxyapatite as a carrier of olanzapine for long-acting antidepression treatment in rats with induced depression
An antidepressant carrier, mesoporous hydroxyapatite olanzapine (mesoHAP-OLZ), was designed to maintain 3weeks of constant medication release. The carrier was intramuscularly (IM) injected, where cellular activity played a role in achieving the goal of constant release. The efficiency of the treatme...
Gespeichert in:
| Veröffentlicht in: | Journal of controlled release 2017-06, Vol.255, p.62-72 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 72 |
|---|---|
| container_issue | |
| container_start_page | 62 |
| container_title | Journal of controlled release |
| container_volume | 255 |
| creator | Shyong, Yan-Jye Wang, Mao-Hsien Kuo, Li-Wei Su, Chang-Fu Kuo, Wei-Ting Chang, Kuo-Chi Lin, Feng-Huei |
| description | An antidepressant carrier, mesoporous hydroxyapatite olanzapine (mesoHAP-OLZ), was designed to maintain 3weeks of constant medication release. The carrier was intramuscularly (IM) injected, where cellular activity played a role in achieving the goal of constant release. The efficiency of the treatment was evaluated from 3 perspectives in in vivo studies: locomotor activities, biomarkers, and learning and memory ability. MesoHAP-OLZ can increase the locomotor activity in rats with induced depression determined by open field test (OFT) and forced swim test (FST). Serotonin (5-HT), one of the most important biomarker in depression can also be increased by mesoHAP-OLZ, leading to increased hippocampus activity as measured by functional magnetic resonance imaging (fMRI). MesoHAP-OLZ can also improve learning and memory ability in rats with induced depression during Morris water maze (MWM) test. Our findings further show that mesoHAP-OLZ can provide long-term drug release with a single IM injection, helping to solve the problem of non-adherent medication intake that often occurs in antidepressant therapy.
After IM injection, mesoHAP-OLZ is engulfed by macrophages and the lysosome/endosome hybrid is broken down by osmosis, which facilitates delivery of OLZ into the bloodstream for various analyses. [Display omitted] |
| doi_str_mv | 10.1016/j.jconrel.2017.03.399 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1886347729</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S016836591630534X</els_id><sourcerecordid>1886347729</sourcerecordid><originalsourceid>FETCH-LOGICAL-c402t-1c68436b428ad8db13d3305e07c828d6ce0ee50fb736cc8f8594e9f330bdb54f3</originalsourceid><addsrcrecordid>eNqFkE1rGzEQhkVJqB23P6FFx1x2K632QzqFYNI2kJJLexZaadaWWUsbSU7iQv57ZOw0x56Ggeed4X0Q-kJJSQltv23KjfYuwFhWhHYlYSUT4gOaU96xohaiOUPzzPGCtY2YoYsYN4SQhtXdRzSrOBNV3ZI5evkF0U8--F3E670J_nmvJpVsAqwiVlirECwE7AfsR-X-qsk6wIMPePRuVSidrFth5ZI1MAWI0XqHUwCVtuAStg4HlSJ-smmdF7PTYPA7-QmdD2qM8Pk0F-jP95vfy5_F3f2P2-X1XaFrUqWC6pbXrO3riivDTU-ZYYw0QDrNK25aDQSgIUPfsVZrPvBG1CCGzPSmb-qBLdDl8e4U_MMOYpJbGzWMuRHk5pJy3mYzXSUy2hxRHXyMAQY5BbtVYS8pkQfzciNP5uXBvCRMZvM59_X0YtdvwfxLvanOwNURgFz0MTuVUVtwWYgNoJM03v7nxSv6Ipss</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1886347729</pqid></control><display><type>article</type><title>Mesoporous hydroxyapatite as a carrier of olanzapine for long-acting antidepression treatment in rats with induced depression</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Shyong, Yan-Jye ; Wang, Mao-Hsien ; Kuo, Li-Wei ; Su, Chang-Fu ; Kuo, Wei-Ting ; Chang, Kuo-Chi ; Lin, Feng-Huei</creator><creatorcontrib>Shyong, Yan-Jye ; Wang, Mao-Hsien ; Kuo, Li-Wei ; Su, Chang-Fu ; Kuo, Wei-Ting ; Chang, Kuo-Chi ; Lin, Feng-Huei</creatorcontrib><description>An antidepressant carrier, mesoporous hydroxyapatite olanzapine (mesoHAP-OLZ), was designed to maintain 3weeks of constant medication release. The carrier was intramuscularly (IM) injected, where cellular activity played a role in achieving the goal of constant release. The efficiency of the treatment was evaluated from 3 perspectives in in vivo studies: locomotor activities, biomarkers, and learning and memory ability. MesoHAP-OLZ can increase the locomotor activity in rats with induced depression determined by open field test (OFT) and forced swim test (FST). Serotonin (5-HT), one of the most important biomarker in depression can also be increased by mesoHAP-OLZ, leading to increased hippocampus activity as measured by functional magnetic resonance imaging (fMRI). MesoHAP-OLZ can also improve learning and memory ability in rats with induced depression during Morris water maze (MWM) test. Our findings further show that mesoHAP-OLZ can provide long-term drug release with a single IM injection, helping to solve the problem of non-adherent medication intake that often occurs in antidepressant therapy.
After IM injection, mesoHAP-OLZ is engulfed by macrophages and the lysosome/endosome hybrid is broken down by osmosis, which facilitates delivery of OLZ into the bloodstream for various analyses. [Display omitted]</description><identifier>ISSN: 0168-3659</identifier><identifier>EISSN: 1873-4995</identifier><identifier>DOI: 10.1016/j.jconrel.2017.03.399</identifier><identifier>PMID: 28392460</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Animals ; Behavior, Animal - drug effects ; Benzodiazepines - administration & dosage ; Benzodiazepines - chemistry ; Benzodiazepines - therapeutic use ; Benzodiazepines - toxicity ; Brain - drug effects ; Brain - metabolism ; Depression - drug therapy ; Depression - metabolism ; Drug Carriers - administration & dosage ; Drug Carriers - chemistry ; Drug Carriers - therapeutic use ; Drug Carriers - toxicity ; Drug Liberation ; Durapatite - administration & dosage ; Durapatite - chemistry ; Durapatite - therapeutic use ; Durapatite - toxicity ; Hydroxyapatite ; Learning and memory abilities ; Locomotion - drug effects ; Locomotor activities ; Male ; Maze Learning - drug effects ; Porosity ; Prolong antidepressant drug carrier ; Rats, Wistar ; Serotonin ; Serotonin - metabolism ; Serotonin Uptake Inhibitors - administration & dosage ; Serotonin Uptake Inhibitors - chemistry ; Serotonin Uptake Inhibitors - therapeutic use ; Serotonin Uptake Inhibitors - toxicity</subject><ispartof>Journal of controlled release, 2017-06, Vol.255, p.62-72</ispartof><rights>2017 Elsevier B.V.</rights><rights>Copyright © 2017 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c402t-1c68436b428ad8db13d3305e07c828d6ce0ee50fb736cc8f8594e9f330bdb54f3</citedby><cites>FETCH-LOGICAL-c402t-1c68436b428ad8db13d3305e07c828d6ce0ee50fb736cc8f8594e9f330bdb54f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S016836591630534X$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28392460$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Shyong, Yan-Jye</creatorcontrib><creatorcontrib>Wang, Mao-Hsien</creatorcontrib><creatorcontrib>Kuo, Li-Wei</creatorcontrib><creatorcontrib>Su, Chang-Fu</creatorcontrib><creatorcontrib>Kuo, Wei-Ting</creatorcontrib><creatorcontrib>Chang, Kuo-Chi</creatorcontrib><creatorcontrib>Lin, Feng-Huei</creatorcontrib><title>Mesoporous hydroxyapatite as a carrier of olanzapine for long-acting antidepression treatment in rats with induced depression</title><title>Journal of controlled release</title><addtitle>J Control Release</addtitle><description>An antidepressant carrier, mesoporous hydroxyapatite olanzapine (mesoHAP-OLZ), was designed to maintain 3weeks of constant medication release. The carrier was intramuscularly (IM) injected, where cellular activity played a role in achieving the goal of constant release. The efficiency of the treatment was evaluated from 3 perspectives in in vivo studies: locomotor activities, biomarkers, and learning and memory ability. MesoHAP-OLZ can increase the locomotor activity in rats with induced depression determined by open field test (OFT) and forced swim test (FST). Serotonin (5-HT), one of the most important biomarker in depression can also be increased by mesoHAP-OLZ, leading to increased hippocampus activity as measured by functional magnetic resonance imaging (fMRI). MesoHAP-OLZ can also improve learning and memory ability in rats with induced depression during Morris water maze (MWM) test. Our findings further show that mesoHAP-OLZ can provide long-term drug release with a single IM injection, helping to solve the problem of non-adherent medication intake that often occurs in antidepressant therapy.
After IM injection, mesoHAP-OLZ is engulfed by macrophages and the lysosome/endosome hybrid is broken down by osmosis, which facilitates delivery of OLZ into the bloodstream for various analyses. [Display omitted]</description><subject>Animals</subject><subject>Behavior, Animal - drug effects</subject><subject>Benzodiazepines - administration & dosage</subject><subject>Benzodiazepines - chemistry</subject><subject>Benzodiazepines - therapeutic use</subject><subject>Benzodiazepines - toxicity</subject><subject>Brain - drug effects</subject><subject>Brain - metabolism</subject><subject>Depression - drug therapy</subject><subject>Depression - metabolism</subject><subject>Drug Carriers - administration & dosage</subject><subject>Drug Carriers - chemistry</subject><subject>Drug Carriers - therapeutic use</subject><subject>Drug Carriers - toxicity</subject><subject>Drug Liberation</subject><subject>Durapatite - administration & dosage</subject><subject>Durapatite - chemistry</subject><subject>Durapatite - therapeutic use</subject><subject>Durapatite - toxicity</subject><subject>Hydroxyapatite</subject><subject>Learning and memory abilities</subject><subject>Locomotion - drug effects</subject><subject>Locomotor activities</subject><subject>Male</subject><subject>Maze Learning - drug effects</subject><subject>Porosity</subject><subject>Prolong antidepressant drug carrier</subject><subject>Rats, Wistar</subject><subject>Serotonin</subject><subject>Serotonin - metabolism</subject><subject>Serotonin Uptake Inhibitors - administration & dosage</subject><subject>Serotonin Uptake Inhibitors - chemistry</subject><subject>Serotonin Uptake Inhibitors - therapeutic use</subject><subject>Serotonin Uptake Inhibitors - toxicity</subject><issn>0168-3659</issn><issn>1873-4995</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkE1rGzEQhkVJqB23P6FFx1x2K632QzqFYNI2kJJLexZaadaWWUsbSU7iQv57ZOw0x56Ggeed4X0Q-kJJSQltv23KjfYuwFhWhHYlYSUT4gOaU96xohaiOUPzzPGCtY2YoYsYN4SQhtXdRzSrOBNV3ZI5evkF0U8--F3E670J_nmvJpVsAqwiVlirECwE7AfsR-X-qsk6wIMPePRuVSidrFth5ZI1MAWI0XqHUwCVtuAStg4HlSJ-smmdF7PTYPA7-QmdD2qM8Pk0F-jP95vfy5_F3f2P2-X1XaFrUqWC6pbXrO3riivDTU-ZYYw0QDrNK25aDQSgIUPfsVZrPvBG1CCGzPSmb-qBLdDl8e4U_MMOYpJbGzWMuRHk5pJy3mYzXSUy2hxRHXyMAQY5BbtVYS8pkQfzciNP5uXBvCRMZvM59_X0YtdvwfxLvanOwNURgFz0MTuVUVtwWYgNoJM03v7nxSv6Ipss</recordid><startdate>20170610</startdate><enddate>20170610</enddate><creator>Shyong, Yan-Jye</creator><creator>Wang, Mao-Hsien</creator><creator>Kuo, Li-Wei</creator><creator>Su, Chang-Fu</creator><creator>Kuo, Wei-Ting</creator><creator>Chang, Kuo-Chi</creator><creator>Lin, Feng-Huei</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20170610</creationdate><title>Mesoporous hydroxyapatite as a carrier of olanzapine for long-acting antidepression treatment in rats with induced depression</title><author>Shyong, Yan-Jye ; Wang, Mao-Hsien ; Kuo, Li-Wei ; Su, Chang-Fu ; Kuo, Wei-Ting ; Chang, Kuo-Chi ; Lin, Feng-Huei</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c402t-1c68436b428ad8db13d3305e07c828d6ce0ee50fb736cc8f8594e9f330bdb54f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Animals</topic><topic>Behavior, Animal - drug effects</topic><topic>Benzodiazepines - administration & dosage</topic><topic>Benzodiazepines - chemistry</topic><topic>Benzodiazepines - therapeutic use</topic><topic>Benzodiazepines - toxicity</topic><topic>Brain - drug effects</topic><topic>Brain - metabolism</topic><topic>Depression - drug therapy</topic><topic>Depression - metabolism</topic><topic>Drug Carriers - administration & dosage</topic><topic>Drug Carriers - chemistry</topic><topic>Drug Carriers - therapeutic use</topic><topic>Drug Carriers - toxicity</topic><topic>Drug Liberation</topic><topic>Durapatite - administration & dosage</topic><topic>Durapatite - chemistry</topic><topic>Durapatite - therapeutic use</topic><topic>Durapatite - toxicity</topic><topic>Hydroxyapatite</topic><topic>Learning and memory abilities</topic><topic>Locomotion - drug effects</topic><topic>Locomotor activities</topic><topic>Male</topic><topic>Maze Learning - drug effects</topic><topic>Porosity</topic><topic>Prolong antidepressant drug carrier</topic><topic>Rats, Wistar</topic><topic>Serotonin</topic><topic>Serotonin - metabolism</topic><topic>Serotonin Uptake Inhibitors - administration & dosage</topic><topic>Serotonin Uptake Inhibitors - chemistry</topic><topic>Serotonin Uptake Inhibitors - therapeutic use</topic><topic>Serotonin Uptake Inhibitors - toxicity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Shyong, Yan-Jye</creatorcontrib><creatorcontrib>Wang, Mao-Hsien</creatorcontrib><creatorcontrib>Kuo, Li-Wei</creatorcontrib><creatorcontrib>Su, Chang-Fu</creatorcontrib><creatorcontrib>Kuo, Wei-Ting</creatorcontrib><creatorcontrib>Chang, Kuo-Chi</creatorcontrib><creatorcontrib>Lin, Feng-Huei</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of controlled release</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Shyong, Yan-Jye</au><au>Wang, Mao-Hsien</au><au>Kuo, Li-Wei</au><au>Su, Chang-Fu</au><au>Kuo, Wei-Ting</au><au>Chang, Kuo-Chi</au><au>Lin, Feng-Huei</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Mesoporous hydroxyapatite as a carrier of olanzapine for long-acting antidepression treatment in rats with induced depression</atitle><jtitle>Journal of controlled release</jtitle><addtitle>J Control Release</addtitle><date>2017-06-10</date><risdate>2017</risdate><volume>255</volume><spage>62</spage><epage>72</epage><pages>62-72</pages><issn>0168-3659</issn><eissn>1873-4995</eissn><abstract>An antidepressant carrier, mesoporous hydroxyapatite olanzapine (mesoHAP-OLZ), was designed to maintain 3weeks of constant medication release. The carrier was intramuscularly (IM) injected, where cellular activity played a role in achieving the goal of constant release. The efficiency of the treatment was evaluated from 3 perspectives in in vivo studies: locomotor activities, biomarkers, and learning and memory ability. MesoHAP-OLZ can increase the locomotor activity in rats with induced depression determined by open field test (OFT) and forced swim test (FST). Serotonin (5-HT), one of the most important biomarker in depression can also be increased by mesoHAP-OLZ, leading to increased hippocampus activity as measured by functional magnetic resonance imaging (fMRI). MesoHAP-OLZ can also improve learning and memory ability in rats with induced depression during Morris water maze (MWM) test. Our findings further show that mesoHAP-OLZ can provide long-term drug release with a single IM injection, helping to solve the problem of non-adherent medication intake that often occurs in antidepressant therapy.
After IM injection, mesoHAP-OLZ is engulfed by macrophages and the lysosome/endosome hybrid is broken down by osmosis, which facilitates delivery of OLZ into the bloodstream for various analyses. [Display omitted]</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>28392460</pmid><doi>10.1016/j.jconrel.2017.03.399</doi><tpages>11</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0168-3659 |
| ispartof | Journal of controlled release, 2017-06, Vol.255, p.62-72 |
| issn | 0168-3659 1873-4995 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1886347729 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Animals Behavior, Animal - drug effects Benzodiazepines - administration & dosage Benzodiazepines - chemistry Benzodiazepines - therapeutic use Benzodiazepines - toxicity Brain - drug effects Brain - metabolism Depression - drug therapy Depression - metabolism Drug Carriers - administration & dosage Drug Carriers - chemistry Drug Carriers - therapeutic use Drug Carriers - toxicity Drug Liberation Durapatite - administration & dosage Durapatite - chemistry Durapatite - therapeutic use Durapatite - toxicity Hydroxyapatite Learning and memory abilities Locomotion - drug effects Locomotor activities Male Maze Learning - drug effects Porosity Prolong antidepressant drug carrier Rats, Wistar Serotonin Serotonin - metabolism Serotonin Uptake Inhibitors - administration & dosage Serotonin Uptake Inhibitors - chemistry Serotonin Uptake Inhibitors - therapeutic use Serotonin Uptake Inhibitors - toxicity |
| title | Mesoporous hydroxyapatite as a carrier of olanzapine for long-acting antidepression treatment in rats with induced depression |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T03%3A24%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Mesoporous%20hydroxyapatite%20as%20a%20carrier%20of%20olanzapine%20for%20long-acting%20antidepression%20treatment%20in%20rats%20with%20induced%20depression&rft.jtitle=Journal%20of%20controlled%20release&rft.au=Shyong,%20Yan-Jye&rft.date=2017-06-10&rft.volume=255&rft.spage=62&rft.epage=72&rft.pages=62-72&rft.issn=0168-3659&rft.eissn=1873-4995&rft_id=info:doi/10.1016/j.jconrel.2017.03.399&rft_dat=%3Cproquest_cross%3E1886347729%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1886347729&rft_id=info:pmid/28392460&rft_els_id=S016836591630534X&rfr_iscdi=true |